drugset / Trial / NCT02395510

A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder

NCT02395510

Phase 4 Completed 27 enrolled Siyan Clinical Corporation
NaSingle-groupOpen-labelTreatment

Summary

The primary aim of this study is to evaluate the efficacy of Vortioxetine in an adult population with a diagnosis of PD. PD is generally treated with benzodiazepines which are very effective but have a high risk for addiction, fall, and cognitive impairment. There is still a need for better treatment for PD for longer term use. There are other drugs within the SSRI/SNRI class which have proven to be effective in treating patients with this diagnosis.

Timeline

Start
2015-05
Primary completion
2016-06
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Vortioxetine Unknown 5 mg
Subject Vortioxetine Unknown 10 mg
Subject Vortioxetine Unknown 20 mg

Indications